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Objective: With improvements in hematopoietic cell transplanta-
tion (HCT) for severe aplastic anemia (SAA), there is a growing pop-
ulation of SAA survivors of HCT. However, there is a paucity of
information regarding late effects in SAA HCT survivors. We ana-
lyzed the burden of malignant and non-malignant late effects in
HCT survivors with acquired SAA.
Methods: A descriptive analysis of 1,718 patients post-HCT for ac-
quired SAA between 1995-2006 reported to the CIBMTR was con-
ducted. Cumulative incidences (CI) of selected late effects are
reported for among ‘‘condition-free’’ (i.e. survivors without a previ-
ous diagnosis of the specified late effect) HCT survivors with SAA.
Results:One-year overall survival for the recipients of related donor
HCT was 83% (80-85) and 62% (58-66) for the recipients of unre-
lated donor HCT. Of the HCT recipients, 1176 (68.5%) patients
with a median age at HCT of 20 years (\1-65) utilized a related do-
nor and 542 (31.5%) patients with a median age at HCT of 20 years
(\1-67) utilized an unrelated donor. Themedian interval from diag-
nosis to transplant was 3 months (\1-348) for related donor HCT
and 14 months (1-318) for unrelated donor HCT. Radiation (of
any type) was utilized in 6% and 78% of related and unrelated donor
HCT cases; respectively. Cy-TBI (68%) was a commonly utilized
conditioning regimen for unrelated donor HCT. The median fol-
low-up is 70 months (1-160) and 67 months (3-182) for related
and unrelated donor HCT; respectively. The 2-year CI of chronic
GVHD was 20% (18-22) and 37% (32-41) in related and unrelated
donor HCT; respectively. Table 1 demonstrates that among 1-year
condition-free survivors, the CI of late effects is greater among un-
related donor HCT survivors and continues to increase.
Conclusion: These findings suggest that HCT survviors with SAA
are a robust and healthy group in general. However, subgroups of pa-
tients undergoing HCT for SAA are at-risk for late effects and must
be educated about and should be monitored for late effects. Sub-
groups of survivors may be at-risk group for a greater burden of spe-S226cific late effects. Ongoing analyses in our cohort will explore selected
risk-factors for late effects after HCT for SAA.
Table 1. Interval specific cumulative incidence of select late
effects among 1-year condition free survivors following related
and unrelated donorHCT for acquired SAAbetween 1995 and
2006 reported to the CIBMTR
Related Donor Unrelated DonorHealth conditions
post transplantN
(at risk)N
(at risk)Cumulative
Incidence % (95% CI)Cumulative
Incidence % (95% CI)Strokes/SeizuresOver next 2 years 707 1.7 (0.9-2.7) 283 1.3 (0.3-2.8)Over next 5 years 416 1.8 (1.0-2.9) 118 2.8 (1.2-5.1)Gonadal DysfunctionOver next 2 years 709 2.6 (1.6-3.8) 273 6.2 (3.8-9.1)Over next 5 years 419 3.0 (2.0-4.3) 108 10.5 (7.3-14.3)Renal FailureOver next 2 years 715 1.1 (0.5-1.9) 287 1.9 (0.7-3.6)Over next 5 years 425 1.4 (0.7-2.3) 127 2.4 (0.9-4.5)Avascular NecrosisOver next 2 years 724 1.4 (0.7-2.3) 276 3.2 (1.5-5.4)Over next 5 years 426 1.8 (1.0-2.8) 117 6.3 (3.6-9.7)CataractsOver next 2 years 734 0.6 (0.2-1.2) 284 2.2 (0.9-4.1)Over next 5 years 433 1.1 (0.5-1.9) 118 5.1 (2.9-8.0)Growth DisturbanceOver next 2 years 735 0.2 (0.0-0.7) 286 1.9 (0.7-3.6)Over next 5 years 433 0.5 (0.1-1.2) 113 7.2 (4.4-10.7)HypothyroidismOver next 2 years 731 0.7 (0.3-1.4) 286 0.6 (0.1-1.8)Over next 5 years 432 1.2 (0.5-2.1) 119 5.5 (2.8-9.0)Solid TumorsOver next 2 years 820 0.6 (0.2-1.1) 276 0.7 (0.1-1.9)Over next 5 years 528 0.7 (0.2-1.3) 121 1.4 (0.4-3.0)64
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Purpose: To determine the influence of concurrent metabolic con-
ditions and lifestyle factors on the risk of cardiovascular (CV) disease
following hematopoietic cell transplantation (HCT).
Methods: HCT survivors treated at the Fred Hutchinson Cancer
Research Center from 1970-2010 were surveyed with respect to se-
lected serious CV outcomes, related metabolic conditions requiring
medications, obesity, lifestyle factors (smoking, physical activity,
diet), and family history beginning in July 2010 (ongoing) using pre-
viously validated self-report questionnaires.
Results: Among 1489 respondents (47% female, median age 57
years, median time since HCT 9 years, 68% allogeneic, 40% with
history of chronic graft versus host disease (GVHD)), the incidence
of serious CV outcomes following HCT included cardiomyopathy
(3.4%), ischemic heart disease (4.4%), and cerebrovascular disease
(4.9%). The prevalence of related metabolic conditions included hy-
pertension (33.8%), dyslipidemia (34.4%), and diabetes (11.8%).
32.8% of patients were currently overweight and 16.4% obese, while
32.1% had a prior history of smoking and 6.3% reported current
smoking. Inmultivariate analyses adjusting forGVHDstatus, hyper-
tension was associated with an increased likelihood of cardiomyopa-
thy (OR1.9, 95%CI 1.0-3.5), while dyslipidemia was associated with
increased likelihoods of ischemic heart disease (OR 3.9, 95%CI 2.1-
7.2) and cerebrovascular disease (OR 2.0, 95%CI 1.2-3.4). Diabetes,
obesity, and smoking (prior or current) were not independently asso-
ciated with any of these serious CV outcomes. Among respondents
free of serious CV disease, healthier diets (ORs 0.5-0.7; p\0.05)
